SEC Form 4 · accession 0001140361-16-061621
Emergent BioSolutions Inc. · EBS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Abdun-Nabi
Officer — President & CEO · Director
Period of report
Apr 18, 2016
Accepted (ET)
Apr 20, 2016 · 11:14 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001367644
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Apr 18, 2016 | S | 2,749 | $40.17 | D | 194,319 | D | |
| Common StockF1,F2,F3 | Apr 18, 2016 | S | 3,580 | $40.17 | D | 190,739 | D | |
| Common StockF1,F2,F3 | Apr 18, 2016 | S | 2,373 | $40.17 | D | 188,366 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.
- F2Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.03 to $40.32, inclusive.